Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Protara Therapeutics ( (TARA) ) has shared an announcement.
Protara Therapeutics announced updates and future milestones for 2025, following a recent public offering that raised approximately $102.7 million. The company plans to use these funds to advance clinical trials of TARA-002 and other programs, potentially enhancing its market position and stakeholder interest in the biotech industry.
More about Protara Therapeutics
Protara Therapeutics is a biopharmaceutical company focused on developing treatments for oncology and rare diseases. The company is advancing its clinical development programs, particularly with its lead candidate TARA-002, which is being investigated for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations.
YTD Price Performance: -0.36%
Average Trading Volume: 2,393,886
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $190.8M
Learn more about TARA stock on TipRanks’ Stock Analysis page.
